
    
      The drug being tested in the study is called TAK-994. TAK-994, is being tested to treat
      participants with NT1. Participants who completed Part B of TAK-994-1501(NCT04096560) will be
      eligible for enrollment in this study.

      This study will enroll approximately 112 patients to receive one of three different TAK 994
      dose for 8 weeks (active drug extension period). Participants will be randomly assigned to
      one of these different TAK 994 doses which will remain undisclosed to the participant and
      study doctor during the study (unless there is an urgent medical need).

      Following the 8-week Active Drug Extension Period, participants will continue into a 4-week
      Double-blind Randomized Withdrawal Period and will receive TAK-994 or Placebo. Participants
      randomized to TAK-994 will continue to receive the same dose as before.

      This multi-center trial will be conducted worldwide. The duration of treatment in this study
      is 12 weeks plus a 2 week safety follow up period Participants will visits the clinic 10
      times after the first dosing.
    
  